TMCnet News

Research and Markets: Global Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market 2015
[May 28, 2015]

Research and Markets: Global Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market 2015


Research and Markets (http://www.researchandmarkets.com/research/7j3dhg/personalized) has announced the addition of the "Personalized Medicine, Targeted Therapeutics and Companion Diagnostic Market 2015: Strategic Analysis of Industry Trends, Technologies, Participants, and Environment" report to their offering.

This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 270 tables & figures over 254 pages. The personalized medicine (global) market is presented as follows:

- By Company (e.g., 23andMe, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD)

- By Geography (US, UK, EU)

- By Segment (Targeted therapeutics, Companion Diagnostics, Esoteric tests, Esoteric lab services)

- By Sub-market (Companion diagnostics & therapeutic, nutrition & wellness, medical technology, pharmacogenomics, consumer genomics)

A wealth of financial data & business strategy information is provided including:

- Company financials, sales & revenue figures

- Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies

- Business Model Strategies for Providers. Provider Systems and Academic Medical Centres

- Business Model Strategies for Payers & Governments

- Private and Public Funding andPersonalized Medicine Reimbursement



- Revisions to Current Payment Systems and intellectual property

- How to Gain Market Penetration in the EU


- Cost-effectiveness and Business Value of Personalized Medicine

- Consumer genomics and POC market

- Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations)

- Comprehensive account of company product portfolios & kits

SWOT, Economic & Regulatory Environment specifics include:

- Key strengths, weaknesses and threats influencing leading player position within the market

- Technologies driving the market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)

- Top fastest growing market segments and emerging opportunities

- Top pharmaceutical companies within the IPM by market share and revenue

- Comprehensive product portfolios, R&D activity and pipeline therapeutics

- M&A activity and future strategies of top personalized medicine pharmacos

- Personalized Medicine Regulation (USA, UK, Germany, France, Spain, Italy)

- CE-marked Personalized Medicine/Diagnostic Tests

- FDA Advances in Personalized Medicine Regulation

This report highlights a number of significant pharmacos and gives details of their operations, products, financials and business strategy.

- 23andMe

- Affymetrix

- Astex Pharmaceuticals

- Atossa Genetics

- CuraGen

- Celera Corporation (Quest Diagnostics)

- Celldex Therapeutics

- deCode Genetics (Amgen)

- Illumina

- Genelex

- Myriad

- Nodality

- Qiagen

Key Topics Covered:

1.0 Executive Summary

2.0 Introduction and Background

3.0 Personalized Medicine Therapeutics and Associated Companion Diagnostics

4.0 Personalized Medicine and Integration into the Healthcare System

5.0 Private and Public Funding and Personalized Medicine Reimbursement

6.0 European Personalized Medicine Market - Payments and Investment

7.0 Personalized Medicine -Business Model Analysis

8.0 Personalized Medicine Main Industry Players

9.0 Personalized Medicine Industry Products and Kits

10.0 Personalized Medicine Market Analysis

11.0 Strengths and Advantages of Personalized Medicine

12.0 Restraints of the Personalized Medicine Market

13.0 Personalized Medicine and Regulatory Policies

14.0 Final Summary and Future Perspectives

For more information visit http://www.researchandmarkets.com/research/7j3dhg/personalized


[ Back To TMCnet.com's Homepage ]